Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj?gren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.

待确认 10 由 RST 发布于 2026/10/2 17:43:30

DOI:10.1016/S0140-6736(24)01211-X
作者：Benjamin A Fisher,?Xavier Mariette,?Athena Papas,?Thomas Grader-Beck,?Hendrika Bootsma,?Wan-Fai Ng,?P L A van Daele,?Stephanie Finzel,?Ghaith Noaiseh,?Sergio Elgueta,?Josef Hermann,?Sara S McCoy,?Esen
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Sjögren's disease is a chronic autoimmune disease with an unmet need for targeted therapies. The aim of the TWINSS study is to evaluate the safety and efficacy of iscalimab, a mo

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

2小时前

科研低保户

202610021757227887726.pdf

2小时前

Book学术机器人

2026/10/2 17:43:30 未找到该文献，机器人已退出，请等待人工下载

2026/10/2 17:43:30 Book学术AI机器人收到请求，开始寻找文献

2026/10/2 17:43:30 已向机器人发送请求

2小时前

RST 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Bioinspired Reflection-Absorption Synergy in Single-Layer Dielectric Metasurfaces for High-Resolution Full-Color Micro-OLED Displays